Abstracts

SYSTEMATIC ANALYSIS OF SARS-CoV-2 INFECTION OF AN ACE2-NEGATIVE HUMAN AIRWAY CELL

Established in vitro models for SARS-CoV-2 infection are limited and include cell lines of non-human origin and those engineered to overexpress ACE2, the cognate host cell receptor. Although Calu-3, a human lung cell line which endogenously expresses ACE2, supports SARS-CoV-2 replication, they are significantly less permissive to infection than other models. Furthermore, ACE2 expression in…

EXCESS OF SARS-CoV-2 SUBGENOMIC RNAs IN CELLS AND FLUIDS DURING ACUTE INFECTION

SARS-CoV-2 is transcribed as genomic RNA (gRNA) and different subgenomic RNAs (sgRNA), allowing variation in viral gene expression. However, the extent and clinical significance of subgenomic transcription remain unknown. We hypothesized that SARS-CoV-2 RNA levels would vary between genome regions and between patients, tissues, and sample types (cells or fluids). We designed and validated 7…

WILMS’ TUMOR 1 IS OVEREXPRESSED IN KAPOSI SARCOMA AND IS REGULATED BY VFLIP/K13

Kaposi Sarcoma (KS), a vascular neoplasm caused by Kaposi sarcoma herpesvirus (KSHV, also called HHV-8), is the most common HIV associated malignancy globally. A National Cancer Institution (NCI) Prioritization Summit ranked Wilms’ Tumor 1 ‘WT1’ as the #1 tumor associated antigen to direct immunotherapy towards. Various forms of WT1 immunotherapies are in development. Following on…

ANTEPARTUM WEIGHT GAIN AND ADVERSE PREGNANCY OUTCOMES IN IMPAACT 2010

Insufficient and excess weight gain during pregnancy have been associated with adverse pregnancy outcomes. We evaluated the association between antepartum weight gain and adverse pregnancy outcomes in secondary analyses of IMPAACT 2010 data. Women with HIV-1 in 9 countries were randomized 1:1:1 at 14-28 weeks gestational age (GA) to start dolutegravir (DTG)+emtricitabine(FTC)/tenofovir alafenamide fumarate (TAF)…

SAFETY/EFFICACY OF DTG VS EFV, TDF VS TAF IN PREGNANCY/POSTPARTUM: IMPAACT 2010 TRIAL

We previously reported safety and virologic efficacy of dolutegravir (DTG)+emtricitabine (FTC)/tenofovir alafenamide fumarate (TAF) vs DTG+FTC/tenofovir disoproxil fumarate (TDF) vs efavirenz (EFV)/FTC/TDF through delivery. We now present results from enrollment through week 50 postpartum (PP). Pregnant women with HIV-1 in 9 countries were randomized 1:1:1 to start open-label DTG+FTC/TAF, DTG+FTC/TDF, or EFV/FTC/TDF at 14-28 weeks…